Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease
Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study
Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation
Phase III Regorafenib Trial Meets PFS Primary Endpoint
Radium-233 Dichloride Increased Overall Survival in Phase III Trial
Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone
Nexavar Phase III Trial Fails To Meet Primary Endpoint
Alimta/Cisplatin Chemotherapy Increased Overall Survival
New Carfilzomib Combination Produces Near Remissions
Trial Data: No Benefit In Adding Perifosine to Capecitabine
Blinatumomab Demonstrates High Response Rate in ALL
MET Inhibitor Improved Time To Progression by 56 Percent
NCI-Approved CTEP Trials For The Month of June
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
